國立虎尾科技大學 |

Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy/ by Shabir Ahmad Ganai.
作者:	Ganai, Shabir Ahmad.
面頁冊數:	XVII, 258 p. 27 illus., 13 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Nucleic Acid Chemistry. -
電子資源:	https://doi.org/10.1007/978-981-15-8179-3
ISBN:	9789811581793

Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy
Ganai, Shabir Ahmad.

Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy[electronic resource] /by Shabir Ahmad Ganai. - 1st ed. 2020. - XVII, 258 p. 27 illus., 13 illus. in color.online resource.

Chapter 1_Epigenetic modifying enzymes. -Chapter 2_Epigenetic modifying enzymes implicated in cancer. -Chapter 3_Classification of histone deacetylases (HDACs). -Chapter 4_Implications of 18 HDAC isoforms in therapeutically monotonous cancers. –Chapter 5_Possible Mechanisms of HDACs in Cancer development -- Chapter 6_Different strategies employed for circumventing cancer resistance (chemo and radio) and mitigating toxicity. -Chapter 7_Limitations of conventional therapeutic regimens in treating cancer. -Chapter 8_Overview of epidrugs with special emphasis on HDAC inhibitors (HDACi) -- Chapter 9_HDAC inhibitors as promising epidrugs for treating cancer. -Chapter 10_ HDAC inhibitors in anticancer monotherapy. -Chapter 11_Distinct groups of histone deacetylase inhibitors (HDACi) based on the structural distinction, HDACs targeted. -Chapter 12_Limited efficacy of HDAC inhibitor-based monotherapy. -Chapter 13_Resistance mechanisms generated by cancer cells against HDACi based monotherapy. -Chapter 14_ Toxicity issue of HDAC inhibitor based monotherapy. -Chapter 15_Combinatorial therapeutic strategies of HDACi. -Chapter 16_Designing Selective HDACi using computational and medicinal chemistry approach. -Chapter 17. Current therapeutic challenges and future directions. .

This book reviews the latest developments in the design, synthesis, and molecular mechanism of action of Histone Deacetylase (HDAC) inhibitors in the context of potential cancer therapy. HDAC inhibitors are emerging as promising anticancer drug molecules that promote growth arrest, differentiation and apoptosis of cancer cells with tumor selective toxicity. The book begins with an overview of various epigenetic modifying enzymes that are involved in cancer transition and progression; before exploring the potential of HDACs in cancer treatment. It provides a classification of HDAC inhibitors based on their structural attributes, and addresses HDAC-induced cytotoxicity.. Lastly, it discusses and assesses the rationale behind therapies that combine HDAC inhibitors with other anticancer agents to treat solid tumors. Given its scope, it offers a valuable resource for all researchers, clinicians, and students working in formulation, drug discovery, oncology, and personalized medicine.

ISBN: 9789811581793

Standard No.: 10.1007/978-981-15-8179-3doiSubjects--Topical Terms:

716485
Nucleic Acid Chemistry.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy
LDR:03655nam a22003975i 4500 001 1028474
003 DE-He213
005 20201123075502.0
007 cr nn 008mamaa
008 210318s2020 si | s |||| 0|eng d
020 $a 9789811581793 $9 978-981-15-8179-3
024 7 $a 10.1007/978-981-15-8179-3 $2 doi
035 $a 978-981-15-8179-3
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
100 1 $a Ganai, Shabir Ahmad. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1297066
245 1 0 $a Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy $h [electronic resource] / $c by Shabir Ahmad Ganai.
250 $a 1st ed. 2020.
264 1 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2020.
300 $a XVII, 258 p. 27 illus., 13 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Chapter 1_Epigenetic modifying enzymes. -Chapter 2_Epigenetic modifying enzymes implicated in cancer. -Chapter 3_Classification of histone deacetylases (HDACs). -Chapter 4_Implications of 18 HDAC isoforms in therapeutically monotonous cancers. –Chapter 5_Possible Mechanisms of HDACs in Cancer development -- Chapter 6_Different strategies employed for circumventing cancer resistance (chemo and radio) and mitigating toxicity. -Chapter 7_Limitations of conventional therapeutic regimens in treating cancer. -Chapter 8_Overview of epidrugs with special emphasis on HDAC inhibitors (HDACi) -- Chapter 9_HDAC inhibitors as promising epidrugs for treating cancer. -Chapter 10_ HDAC inhibitors in anticancer monotherapy. -Chapter 11_Distinct groups of histone deacetylase inhibitors (HDACi) based on the structural distinction, HDACs targeted. -Chapter 12_Limited efficacy of HDAC inhibitor-based monotherapy. -Chapter 13_Resistance mechanisms generated by cancer cells against HDACi based monotherapy. -Chapter 14_ Toxicity issue of HDAC inhibitor based monotherapy. -Chapter 15_Combinatorial therapeutic strategies of HDACi. -Chapter 16_Designing Selective HDACi using computational and medicinal chemistry approach. -Chapter 17. Current therapeutic challenges and future directions. .
520 $a This book reviews the latest developments in the design, synthesis, and molecular mechanism of action of Histone Deacetylase (HDAC) inhibitors in the context of potential cancer therapy. HDAC inhibitors are emerging as promising anticancer drug molecules that promote growth arrest, differentiation and apoptosis of cancer cells with tumor selective toxicity. The book begins with an overview of various epigenetic modifying enzymes that are involved in cancer transition and progression; before exploring the potential of HDACs in cancer treatment. It provides a classification of HDAC inhibitors based on their structural attributes, and addresses HDAC-induced cytotoxicity.. Lastly, it discusses and assesses the rationale behind therapies that combine HDAC inhibitors with other anticancer agents to treat solid tumors. Given its scope, it offers a valuable resource for all researchers, clinicians, and students working in formulation, drug discovery, oncology, and personalized medicine.
650 2 4 $a Nucleic Acid Chemistry. $3 716485
650 2 4 $a Gene Function. $3 782134
650 2 4 $a Gene Expression. $3 582691
650 1 4 $a Cancer Research. $3 668358
650 0 $a Nucleic acids. $3 788506
650 0 $a Medical genetics. $3 678508
650 0 $a Gene expression. $3 581931
650 0 $a Cancer research. $3 1253664
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9789811581786
776 0 8 $i Printed edition: $z 9789811581809
776 0 8 $i Printed edition: $z 9789811581816
856 4 0 $u https://doi.org/10.1007/978-981-15-8179-3
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)